During the past decade, Oncology Hematology Care, Inc. conducted 149 clinical trials. In the 10-year time frame, 149 clinical trials started and 164 clinical trials were completed, i.e. on average, 110.1% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 88 clinical trials were completed. i.e. 266.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oncology Hematology Care, Inc." #1 sponsor was "SCRI Development Innovations, LLC" with 67 trials, followed by "National Cancer Institute (NCI)" with 36 trials sponsored, "SWOG Cancer Research Network" with 20 trials sponsored, "Hoffmann-La Roche" with 16 trials sponsored and "Alliance for Clinical Trials in Oncology" with 16 trials sponsored. Other sponsors include 146 different institutions and companies that sponsored additional 78 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oncology Hematology Care, Inc." #1 collaborator was "National Cancer Institute (NCI)" with 45 trials as a collaborator, "Genentech, Inc." with 19 trials as a collaborator, "Bristol-Myers Squibb" with 12 trials as a collaborator, "Eli Lilly and Company" with 10 trials as a collaborator and "Novartis" with 10 trials as a collaborator. Other collaborators include 104 different institutions and companies that were collaborators in the rest 61 trials.

According to Clinical.Site data, the most researched conditions in "Oncology Hematology Care, Inc." are "Breast Cancer" (24 trials), "Colorectal Cancer" (9 trials), "Metastatic Breast Cancer" (9 trials), "Recurrent Squamous Cell Lung Carcinoma" (9 trials) and "Lung Cancer" (8 trials). Many other conditions were trialed in "Oncology Hematology Care, Inc." in a lesser frequency.

Most popular intervention types in "Oncology Hematology Care, Inc." are "Drug" (279 trials), "Other" (68 trials), "Biological" (46 trials), "Procedure" (20 trials) and "Radiation" (10 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (42 trials), "Carboplatin" (32 trials), "Placebo" (30 trials), "Docetaxel" (27 trials) and "Bevacizumab" (21 trials). Other intervention names were less common.

The vast majority of trials in "Oncology Hematology Care, Inc." are 249 trials for "All" genders, 42 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are NaN active trials in "Oncology Hematology Care, Inc.". undefined are not yet recruiting, 29 are recruiting, 72 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 158 completed trials in Oncology Hematology Care, Inc., undefined suspended trials, and 37 terminated clinical trials to date.

Out of the total trials that were conducted in Oncology Hematology Care, Inc., 34 "Phase 1" clinical trials were conducted, 180 "Phase 2" clinical trials and 108 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".

Oncology Hematology Care, Inc. has several departments that took part in Clinical trials: "Oncology Hematology Care Inc-Blue Ash" - 96 trials, "Oncology Hematology Care Inc-Healthplex" - 85 trials, "Oncology Hematology Care Inc-Mercy West" - 80 trials, "Oncology Hematology Care Inc-Eden Park" - 77 trials, "Oncology Hematology Care Inc-Kenwood" - 162 trials, "Oncology Hematology Care, Inc." - 3 trials, "Oncology Hematology Care - SCRI" - 2 trials